Lung cancer remains the leading cause of cancer death, claiming more lives than breast, prostate, and colon cancer combined.1 Updated data show that 5-year survival rates have increased to approximately 30%, largely due to stage shift and modern therapies.2 The National Lung Screening Trial (NLST; NCT00047385) data demonstrated a 20% mortality reduction with low-dose computed tomography (LDCT) vs chest x-ray; the NELSON trial (ISRCTN63545820) confirmed a 24% to 26% reduction using volumetric CT, with women deriving greater benefit.1,3 Yet its uptake remains below 20%.4
“If lung cancer is caught early, the outlook is completely different. Stage IV survival is under 10%, but stage I can be close to 90%. Early detection means we can often do a curative surgery and help patients live disease free, which not only improves survival but also quality of life.” – Eric L. Grogan, MD, MPH
“The state of Kentucky is a great example of what happens when screening programs are done well. Even with only about 20% of eligible people getting screened, they’ve already seen fewer late-stage cancers and better survival. That shows how powerful screening can be when implemented effectively.” – Stephen A. Deppen, PhD
Key Takeaways
- LDCT screening improves survival by detecting cancer earlier, shifting diagnoses from advanced stages to early stages. NLST data showed an approximately 20% reduction in mortality, and the NELSON trial data confirmed a 24% to 26% reduction, with greater benefit observed in women.
- The USPSTF expanded eligibility criteria for LDCT to improve equity. The current recommendation is for an annual LDCT for adults aged 50 to 80 years with at least 20 pack‑years and 15 or fewer years since quitting.
- Structured reporting via Lung‑RADS reduces unnecessary work‑ups; v2022 adds refinements for cysts and airway nodules.
- Risk models (eg, TREAT 2.0) and AI tools such as Optellum help personalize decisions and prevent loss to follow‑up, while blood‑based adjuncts (DELFI, Nodify) complement imaging for screening triage and indeterminate nodules.
- Navigational bronchoscopy offers a safer diagnostic approach than CT‑guided biopsy; the VERITAS trial data show approximately 1% vs approximately 30% pneumothorax rates.
What are the current best practices for lung cancer detection?
The United States Preventive Services Task Force recommends annual LDCT for adults aged 50 to 80 years with at least 20 pack-years and 15 or fewer years since quitting.5 Despite coverage, fewer than 18% of eligible individuals are screened.4 Barriers to screening include stigma, fatalism, and the complexity of shared decision-making.
The Lung CT Screening Reporting and Data System (Lung-RADS), introduced in 2014 and updated in 2019 and 2022, standardizes reporting and reduces false positives compared with early trial data.6,7 However, the eligibility criteria still miss many cases; only approximately 40% of patients diagnosed with lung cancer would have qualified under current rules.
Risk-based models such as the Prostate, Lung, Colorectal, and Ovarian (PLCOM2012) and Vanderbilt University’s Thoracic Research Evaluation And Treatment (TREAT) 2.0 improve the identification of high-risk patients, including women and nonsmokers.8 TREAT 2.0 incorporates a novel method addressing missing data in predictive modeling: the pattern submodel approach.
What are some key advances in early lung cancer detection and risk assessment?
Data from a landmark randomized controlled trial published in the New England Journal of Medicine demonstrated that electromagnetic navigational bronchoscopy (ENB) is noninferior to CT-guided transthoracic biopsy for diagnosing peripheral lung nodules. Led by Fabien Maldonado, MD, MSc, the study showed ENB provides comparable diagnostic accuracy while significantly reducing complications, with pneumothorax occurring in approximately 1% of ENB cases compared with nearly 30% for CT-guided biopsy.9 This advance positions ENB as a safer, first-line option for tissue sampling in patients with suspicious lung nodules and represents a major step forward in early lung cancer detection and patient safety.
“These findings support a shift toward navigational bronchoscopy as a preferred diagnostic approach for appropriate patients, offering comparable accuracy with far fewer risks.” — Fabien Maldonado, MD, MSc
Beyond procedural advances, several technologies are reshaping early detection and risk assessment:
